Table 1. Characteristics and initial laboratory data at the onset day of dengue fever (D0) among 4,069 patients.
| Variables | Fatal patients, n = 37 | Surviving patients, n = 4,032 | p values |
|---|---|---|---|
| Age, years | 74.9±12.0 | 47.8±21.5 | <0.001 |
| Male gender | 14 (37.8%) | 2039 (50.6%) | 0.12 |
| Days between illness onset and diagnosis | 1 (0–5) | 1 (0–67) | 0.05 |
| Days between illness onset and death | 4 (0–7) | --- | |
| Days between diagnosis and death | 2 (-1-7) | --- | |
| Ever hospitalization after the illness onset | 24 (64.9%) | 534 (13.2%) | <0.001 |
| Diagnosis of viral hepatitis B or C a | 0 (0%) | 13 (0.3%) | 1.00 |
| Diseases of hematological disorders a | 0 (0%) | 215 (5.4%) | 0.26 |
| Diagnosis of alcohol dependence a | 0 (0%) | 1 (0%) | 1.00 |
| Diagnosis of hypertensive disease a | 8 (27.6%) | 420 (10.6%) | 0.05 |
| Diagnosis of acute hepatitis or liver failure a | 0 (0%) | 62 (1.6%) | 1.00 |
| Aspartate transaminase (U/L)b | 185 (47–1,481) | 35 (17–1,019) | <0.001 |
| Alanine transaminase (U/L)c | 33.5 (10–357) | 16 (10–491) | 0.10 |
| Activated partial thromboplastin time (seconds)d | 39.7 (30.9–60.8) | 38 (27.5–93.2) | 0.65 |
| Platelet (x103/μl)e | 113 (19–228) | 166 (5–567) | 0.38 |
Note: Data are expressed as case number (%), mean ± standard deviation, median (range)
a Twenty-nine records from 29 patients in the fatal group and 3,971 records from 3,971 patients in the survivor group
b Six test results from six patients in the fatal group and 529 test results from 526 patients in the survivor group were provided at D0.
c Sixteen test results from sixteen patients in the fatal group and 1,105 test results from 1,097 patients in the survivor group were provided at D0.
d Seven test results from seven patients in the fatal group and 306 test results from 305 patients in the survivor group were provided at D0.
e Three test results from three patients in the fatal group and 546 test results from 542 patients in the survivor group were provided at D0.